ARTICLE | Emerging Company Profile
Tune: Fine-tuning gene expression through epigenetic editing
Newco emerges with $40M to control gene expression levels by altering the 98% of the genome outside of coding regions
December 14, 2021 11:09 PM UTC
Tune is applying gene editing tools to the epigenome to treat disease by controlling gene expression, including multiple genes simultaneously.
Launched Dec. 2, Tune Therapeutics Inc. builds on the work of co-founders Fyodor Urnov and Charlie Gersbach. Urnov, a University of California Berkeley professor and scientific director of the Innovative Genomics Institute, worked at Sangamo Therapeutics Inc. (NASDAQ:SGMO) in 2000-16 where he co-led efforts to develop a toolbox of genetic and epigenetic editing techniques as a therapeutic approach...